Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Keymed Biosciences, Inc. ( (HK:2162) ) is now available.
Keymed Biosciences Inc. reported a significant increase in revenue for the first half of 2025, driven by the successful sales of its core pipeline product, Stapokibart, which has received approvals for multiple indications. The company is advancing several Phase III clinical studies for Stapokibart and collaborating with AstraZeneca on the development of CMG901 for advanced solid tumors. Despite the positive revenue growth, the company experienced a loss, although it was substantially reduced compared to the previous year. The resignation of the Chief Financial Officer and Joint Company Secretary was also announced, marking a notable change in the company’s leadership.
The most recent analyst rating on (HK:2162) stock is a Hold with a HK$66.00 price target. To see the full list of analyst forecasts on Keymed Biosciences, Inc. stock, see the HK:2162 Stock Forecast page.
More about Keymed Biosciences, Inc.
Keymed Biosciences Inc. operates in the biopharmaceutical industry, focusing on the research and development of innovative therapies. The company is primarily engaged in developing antibody-based drugs for the treatment of various diseases, with a market focus on conditions such as atopic dermatitis, chronic rhinosinusitis, and advanced solid tumors.
Average Trading Volume: 4,550,245
Technical Sentiment Signal: Buy
Current Market Cap: HK$20B
Find detailed analytics on 2162 stock on TipRanks’ Stock Analysis page.